Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/11930| Title: | BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition. | Austin Authors: | Andrews, Miles C;Behren, Andreas;Chionh, Fiona;Mariadason, John M ;Vella, Laura J;Do, Hongdo;Dobrovic, Alexander ;Tebbutt, Niall C ;Cebon, Jonathan S | Affiliation: | Joint Ludwig-Austin Oncology Unit, Austin Health, Victoria, Australia | Issue Date: | 4-Nov-2013 | Publication information: | Journal of Clinical Oncology 2013; 31(35): e448-51 | URI: | https://ahro.austin.org.au/austinjspui/handle/1/11930 | DOI: | 10.1200/JCO.2013.50.4118 | Journal: | Journal of Clinical Oncology | URL: | https://pubmed.ncbi.nlm.nih.gov/24190114 | Type: | Journal Article | Subjects: | Cell Proliferation.drug effects Colonic Neoplasms.drug therapy.genetics.pathology Humans Imidazoles.therapeutic use MAP Kinase Kinase 1.antagonists & inhibitors.metabolism MAP Kinase Kinase 2.antagonists & inhibitors.metabolism Male Middle Aged Mutation Oximes.therapeutic use Protein Kinase Inhibitors.therapeutic use Proto-Oncogene Proteins.genetics Proto-Oncogene Proteins B-raf.antagonists & inhibitors.metabolism Pyridones.therapeutic use Pyrimidinones.therapeutic use Treatment Outcome ras Proteins.genetics |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.